Raksha Jain
Overview
Explore the profile of Raksha Jain including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
91
Citations
1690
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
L K, E G, S P S, Chandra S, Jain R
F1000Res
. 2025 Feb;
13:890.
PMID: 39959437
Background: Data Envelopment Analysis (DEA) methodology is considered the most suitable approach for relative performance efficiency calculation for banks as it is believed to be superior to traditional ratio-based analysis...
2.
Szczesniak R, Andrinopoulou E, Li H, Jain R, Mayer-Hamblett N, Ostrenga J, et al.
J Cyst Fibros
. 2025 Feb;
PMID: 39929763
Background: Increased variability in forced expiratory volume in 1 s of % predicted (FEVpp) has been associated with accelerated lung function decline in individuals with cystic fibrosis (CF). Lung function...
3.
Godfrey E, Magaret A, Roe A, Taylor-Cousar J, Walker P, Langfelder-Schwind E, et al.
J Cyst Fibros
. 2025 Jan;
PMID: 39848844
Background: Reproductive life planning is key, now that people with cystic fibrosis (pwCF) may live into their 60s. This study explores contraceptive use, pregnancy trends, and whether concomitant cystic fibrosis...
4.
5.
Hergenroeder G, Todd J, Ostrenga J, Goss C, Jain R, Morgan W, et al.
J Cyst Fibros
. 2024 Oct;
24(1):135-141.
PMID: 39472230
Background: This study aims to characterize the uptake of elexacaftor/tezacaftor/ivacaftor (ETI) following Food and Drug Administration (FDA) approval in October 2019. Methods: People with cystic fibrosis (PwCF) ≥12 years enrolled...
6.
Ratti G, Smith H, Mirfakhraee S, Reisch J, Cohen L, Jain R, et al.
J Cyst Fibros
. 2024 Oct;
24(1):47-52.
PMID: 39419654
Background: The constellation of hypertension, truncal obesity, impaired fasting glucose, low high-density lipoprotein, and hypertriglyceridemia is known as metabolic syndrome (MetSyn) and is associated with cardiovascular and other diseases. Elexacaftor-tezacaftor-ivacaftor...
7.
Jain R, Peng G, Lee M, Keller A, Cosmich S, Reddy S, et al.
Chest
. 2024 Sep;
167(2):348-361.
PMID: 39343292
Background: Cystic fibrosis (CF) transmembrane conductance regulator (CFTR) modulators are available to the majority of people with CF in the United States; little is known about pregnancy outcomes with modulator...
8.
Mall M, Davies J, Donaldson S, Jain R, Chalmers J, Shteinberg M
Eur Respir Rev
. 2024 Sep;
33(173).
PMID: 39293854
Chronic airway inflammation is a central feature in the pathogenesis of bronchiectasis (BE), which can be caused by cystic fibrosis (CFBE; hereafter referred to as CF lung disease) and non-CF-related...
9.
Taylor-Cousar J, Fakhari S, Allison L, Bartels D, Jain R, Han S
J Cyst Fibros
. 2024 Sep;
24(1):19-20.
PMID: 39289139
No abstract available.
10.
Davies J, Polineni D, Boyd A, Donaldson S, Gill D, Griesenbach U, et al.
Am J Respir Crit Care Med
. 2024 Sep;
210(12):1398-1408.
PMID: 39236265
Cystic fibrosis (CF) is a genetic disease caused by mutations in the (cystic fibrosis transmembrane conductance regulator) gene. Although CF is a multiorgan disease, the leading causes of morbidity and...